### Advertising Analysis Review

Source: Advertising Analysis Report, April 2007

## Top 10 Advertised Drug Classes January-April 2007

COX-2 inhibitors		\$2,556,900 (+296%)
Cholesterol reducers		\$2,403,500 (-18%)
Antiasthmatics/bronchodilators		\$2,176,400 (+17%)
Angiotensin II antagonis	sts	\$1,836,500 (-5%)
Diabetes diagnosis and t	therapy \$	51,501,000 (+12%)
Ulcer therapy	\$1,3	27,400 (-18%)
Analgesics-narcotics	\$1,32	5,900 (+11%)
Vaccines	\$1,298,3	00 (+249%)
Contraceptives	\$928,30	0 (-14%)
ACE inhibitors	\$880,100	(+15%)

# Advertised Products Ommer diseases can be supported as a single copy for personal and print a single copy for personal and person

**Prexige** \$874,200 (+999%) Alvesco Crestor \$778,200 (-26%) Lipitor \$750,500 (-18%) Avapro \$695,200 (+17%) Avandia \$675,600 (+48%) Diovan \$642,000 (-17%) Caduet \$562,800 (-18%) \$519,300 (-20%) Lyrica \$513,900 (-18%) Altace

To find out more about these figures, contact your STA representative:

John Donnet: (514) 695-8393,

ext. 227

Carlo Viola: (905) 564-7700,

ext. 201

\$2,286,300 (+999%)



### motivation matters



We craft communications that motivate and inspire audiences.
Whether it's hundreds of employees at a live event, a single patient visiting a web site, or a physician learning about a promising new product, at Vincelli, we know how to get the message out.

### Vincelli communications.

Content that shows www.vincelli.com 514.866.1222